Chromadex (NASDAQ:CDXC) received a $8.00 target price from equities researchers at HC Wainwright in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 41.59% from the company’s previous close.

CDXC has been the subject of several other research reports. BidaskClub cut shares of Chromadex from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Zacks Investment Research cut shares of Chromadex from a “buy” rating to a “hold” rating in a report on Wednesday, November 29th. ValuEngine cut shares of Chromadex from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Chromadex in a report on Monday, September 25th. They set a “buy” rating and a $7.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $7.50.

Chromadex (CDXC) opened at $5.65 on Tuesday. The stock has a market cap of $314.95, a price-to-earnings ratio of -40.35 and a beta of 1.37. Chromadex has a fifty-two week low of $2.26 and a fifty-two week high of $7.24. The company has a quick ratio of 4.12, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Chromadex (NASDAQ:CDXC) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02). Chromadex had a negative return on equity of 47.30% and a negative net margin of 21.89%. sell-side analysts expect that Chromadex will post -0.15 EPS for the current year.

In other Chromadex news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of Chromadex stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $6.52, for a total value of $185,031.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder River Ventures Ltd Champion acquired 731,707 shares of the business’s stock in a transaction on Friday, November 17th. The stock was purchased at an average cost of $4.10 per share, with a total value of $2,999,998.70. The disclosure for this purchase can be found here. Company insiders own 11.59% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Granite Investment Partners LLC increased its holdings in Chromadex by 5.7% in the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock valued at $1,076,000 after buying an additional 13,599 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Chromadex by 870.6% in the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock valued at $698,000 after buying an additional 163,817 shares in the last quarter. Finally, Thompson Davis & CO. Inc. purchased a new position in Chromadex in the third quarter valued at $128,000. 5.89% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Chromadex (CDXC) Given a $8.00 Price Target at HC Wainwright” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/01/23/chromadex-cdxc-given-a-8-00-price-target-at-hc-wainwright.html.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.